Nanobiotix
NBTX
5 hedge funds and large institutions have $12.2M invested in Nanobiotix in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 9.93% → 9.93% (+0%)
0% less capital invested
Capital invested by funds: $12.2M → $12.2M (-$23.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.91K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Baillie Gifford & Co
Edinburgh,
United Kingdom
| $4.62M | – | – | – |
|
|
PA
2
Perceptive Advisors
New York
| $3.89M | – | – | – |
|
|
AG
3
Artal Group
Luxembourg
| $3.67M | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $13.9K | +$2.91K | +755 | +25% |
|
|
AWM
5
Activest Wealth Management
Aventure,
Florida
| $1.04K | – | – | – |
|
NBTX Hedge Fund Activity: Q4 2022 in Review
5 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Nanobiotix (NBTX) for Q4 2022, worth a combined $12.2M — down 0.19% from $12.2M a quarter earlier.
Fund positioning in NBTX was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $2.91K.
- 5 institutional investors held Nanobiotix (NBTX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $12.2M of Nanobiotix stock for Q4 2022, down 0.19% quarter-over-quarter.
- 0 funds opened new Nanobiotix positions in Q4 2022 and 0 closed out.
- The largest Nanobiotix buyer in Q4 2022 was UBS Group, an estimated $2.91K added.
Based on aggregated 13F filings for Q4 2022.